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1. Introduction
This is the 5th hypertension guideline published by the Southern 
African Hypertension Society (SAHS). It is an important step 
towards implementing a national standard to improve the quality 
of care for persons living with hypertension. The realistic objectives 
described can be applied widely and aim to diminish the impact 
of hypertension and related cardiovascular disease (CVD) risk in 
South Africa. Previous versions of the SAHS guideline emphasised 
improved diagnosis and treatment, tighter control and risk factor 
stratification.1-4 Other guidelines support the same trends and the 
movement to evidence-based strategies.5-10 The SAHS continuously 
reviews its guideline, given the changing nature of the evidence.
Using criteria of BP ≥160/95 mmHg or persons aged >18 years 
receiving antihypertensive medication, the 1998 South African 
Demographic and Health Survey estimated that there were 3.3 
million people with hypertension in the country.11 Acceptance of 
the international definition of hypertension (BP ≥140/90 mmHg; 
used in this guideline) adds a further 2.7 million people to this 
hypertensive population.11 CVD was previously ranked as the second 
highest cause-of-death category in South Africa.12 This has major cost 
implications for a developing country and requires a national strategy 
for prevention and management. 
Hypertension is a global health burden affecting developed and 
developing countries, including South Africa.13 The high prevalence 
of hypertension worldwide contributes to the present and anticipated 
pandemic of CVD, which is of particular concern in developing 
countries.13 The control of hypertension, together with the curbing 
of other major risk factors such as cigarette smoking, dyslipidaemia 
and diabetes mellitus, constitutes the ideal approach to the primary 
prevention of atherosclerotic disease, and remains a major challenge 
for the community. The trend towards comprehensive cardiovascular 
(CV) risk factor management is the internationally accepted model 
of care.14
Hypertension is a major and costly contributor to CVD: it 
accounted for R4 - 5 billion in direct and indirect expenditure in 
1991,15 and was previously shown to constitute 7.5% of the direct 
total healthcare spend in South Africa.16 This guideline has adopted 
an evidence-based approach to the estimation of CVD risk, intended 
to allow the treatment of patients at highest risk and those who can 
benefit most from lifestyle and drug interventions at the lowest cost, 
given the country’s limited resources.17
2. Objective and methodology
The objective of this guideline is to promote evidence-based, 
accessible, and comprehensive management of hypertension by 
healthcare professionals in the public and private sectors in South 
Africa. It should act as a resource document to inform hypertensive 
patients of the national approach to hypertension care. For 
development of this guideline, hypertension and CVD treatment and 
prevention guidelines were reviewed, as well as hypertension trials 
reporting clinical end-points, including individuals with important 
co-morbidities, such as diabetes mellitus and chronic kidney disease 
(CKD).
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Outcomes. Extensive data from randomised controlled trials have 
shown the benefit of treating hypertension. The target blood 
pressure (BP) for antihypertensive management is systolic <140 
mmHg and diastolic <90 mmHg with minimal or no drug side-
effects; however, stricter BP control is required for patients with 
end-organ damage, co-existing risk factors and co-morbidity, e.g. 
diabetes mellitus. The reduction of BP in the elderly and in those 
with severe hypertension should be achieved gradually over 1 
month. Co-existent risk factors should also be controlled.
Benefits. Benefits of management include reduced risks of stroke, 
cardiac failure, chronic kidney disease and coronary heart disease.
Recommendations. The correct BP measurement procedure 
is described, and evaluation of cardiovascular risk factors and 
recommendations for antihypertensive therapy are stipulated. The 
total cardiovascular disease risk profile should be determined for 
all patients to inform management strategies. Lifestyle modification 
and patient education are cornerstones in the management of every 
patient. Major indications, precautions and contraindications to 
each recommended antihypertensive drug are listed. Combination 
therapy should be considered ab initio if the BP is ≥20/10 mmHg 
above goal. First-line drug therapy for uncomplicated hypertension 
includes low-dose thiazide-like diuretics, calcium channel blockers 
(CCBs) or angiotensin-converting enzyme inhibitors (ACE-
Is) (or ARBs - angiotensin II receptor blockers). If the target 
BP is not obtained, a second antihypertensive should be added 
from the aforementioned list. If the target BP is still not met, 
the third remaining antihypertensive agent should be used. In 
black patients either thiazide-like diuretics or CCBs can be used 
initially, because response rates are better than with ACE-Is or 
β-blockers. In treating resistant hypertension, a centrally acting 
drug, vasodilator, α-blocker, spironolactone or β-blocker should be 
added. This guideline includes management of specific situations, 
i.e. hypertensive emergency and urgency, severe hypertension with 
target organ damage, hypertension in diabetes mellitus, resistant 
hypertension, fixed drug combinations, new trials in hypertension, 
and interactions of antihypertensive agents with other drugs.
Validity. The guideline was developed by the Southern African 
Hypertension Society.
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3. Measurement of BP
Blood pressure (BP) measurement is a vital clinical sign, but 
can be poorly performed by healthcare professionals. Published 
recommendations of the European Hypertension Society and the 
American Heart Association are endorsed by the Hypertension 
Working Group.5,18
3.1 Generic measurement principles
These recommendations are generic and apply equally to all 
validated devices, especially in clinic and self BP monitoring (SBPM); 
considerations include arm position, posture of the patient, cuff 
size and the number of readings that should be taken. BP should 
be recorded using an approved device with the patient seated for at 
least 5 minutes before measurement (with the back supported, and 
arm bared and resting on a surface at heart-level). Patients should 
not have smoked, or ingested caffeine-containing beverages or food 
in the preceding 30 minutes. In persons aged 60+ years, those with 
diabetes mellitus and others at risk (Table III), the BP should also 
be recorded after the patient has stood for 1 minute, to document 
postural hypotension.
An appropriate size cuff should be used: a standard cuff (12 cm) 
for a normal arm and a larger cuff (15 cm) for an arm with a mid-
upper circumference >33 cm; the bladder within the cuff should 
encircle 80% of the arm. If an undersized cuff is used, the BP can be 
overestimated (under-cuffing); the BP can equally be underestimated 
(over-cuffing) if the cuff and bladder are too large.
Systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) should be recorded. BP should be measured in both arms 
at the initial consultation; if there is a discrepancy, it should 
subsequently be taken in the arm with the higher BP. SBP should 
be estimated first by palpation to avoid missing the auscultatory 
gap. SBP is measured at the first appearance of sound (Phase I) 
and DBP is measured at the disappearance of sound (Phase V). 
Measurement at Phase V is also recommended in pregnancy. In 
cardiac arrhythmia (e.g. atrial fibrillation) the highest Phase I and 
lowest Phase V are recorded as the SBP and DBP, respectively. 
Circumstances when both Phase IV (muffling) and Phase V 
should be recorded include aortic regurgitation, pregnancy and 
severe anaemia.
The BP recorded should be the average of 2 readings taken 1 minute 
apart. If the first 2 readings differ by >5 mmHg, additional readings 
should be taken. When the initial SBP is between 140 and 160 mmHg, 
or the DBP is between 90 and 100 mmHg, repeat measurements 
should be performed on 3 separate occasions within a period of 2 
months, to determine whether a diagnosis of hypertension is valid. 
All measurements should preferably be taken at the same time of the 
day and in the same arm.
The elderly may present considerably variable BP measurements. 
It may be advisable to check the standing BP in hot weather – 
particularly in diabetics, the elderly, and those who have symptoms 
of postural hypotension.19 The most common form of hypertension is 
isolated systolic hypertension (ISH), attributed to the stiffening of the 
large arteries that occurs with ageing.
The BP measurement device and its attachments (tubing, cuff, and 
valve) must be serviced and calibrated at least once each year.
3.2 Mercury sphygmomanometer
There is increasing criticism of the use of mercury sphygmo- 
manometers: mercury is inert and does not degrade,20 but is not 
toxic to patients or operators, provided that the device is intact; 
however, mercury becomes a major environmental hazard when 
it is discarded. There are international moves to replace mercury 
sphygmomanometers with battery-operated digital devices; however, 
in South Africa and other developing countries, there is concern 
about the availability of accurate devices, and the safe disposal of 
lead-containing batteries. If a mercury sphygmomanometer needs 
replacement, an inexpensive solar-powered validated oscillometric 
device should be considered.21 
3.3 Self- and ambulatory BP monitoring
SBPM and ambulatory blood pressure monitoring (ABPM) is 
recommended in selected circumstances and for selected target 
groups:18 
•	 In suspected ‘white-coat’ (higher readings in the office compared 
with readings outside) or masked hypertension (normal readings 
in the office and higher readings outside)
•	 To guide antihypertensive medication, especially in high-risk 
groups (e.g. the elderly and diabetics)
•	 In refractory hypertension
•	 To improve compliance with treatment (SBPM only).
Masked hypertension should be suspected if target organ 
damage (TOD) progresses or remains unresolved, despite BP 
control in the clinic. All devices used for SBPM and ABPM should 
be validated properly with the following independent websites: 
http://www.dableducational.com and http://afssaps.sante.fr.
For SBPM, only upper-arm devices are recommended, but are 
unsuitable in patients with sustained arrhythmias. These devices 
should not be used for BP measurement during exercise, and they 
are not as specific as ABPM devices for the diagnosis of white-
coat hypertension. Ideally, a reliable mean BP value should be 
established by calculating the average of 2 early morning and 2 late 
afternoon readings taken over 5 days. Patients must discuss any 
proposed change in medication with their healthcare professional. 
The advantages of SBPM are: improved assessment of drug effects; 
detection of causal relationships between adverse events and BP 
response; and improved compliance. The disadvantages include an 
increase in anxiety and the risk of self-medication.
ABPM provides the most accurate method to diagnose 
hypertension, assess BP control and predict outcome.22 In patients 
with a raised clinic BP, ABPM was shown to reduce misdiagnosis 
and save costs.23 Additional costs of ABPM were counter-balanced 
by the costs saved by better-targeted treatment. ABPM can also 
assess nocturnal BP control and BP variability, which are important 
predictors of adverse outcome; however, this is limited by access to 
equipment – particularly in the public sector – and the impracticalities 
of regular 24-hour monitoring (Table I).
4. Cardiovascular disease risk 
stratification
The principle of assessing and managing multiple major risk factors 
for CVD is unanimously accepted; however, there is much debate on 
which method of risk stratification to use.
4.1 Rationale for cardiovascular risk assessment
The rationale for assessing CVD risk is that certain risk factors confer 
a great possibility of morbidity and mortality. It is assumed that 
identification of individuals at highest risk allows scarce resources 
Summary
•	 Use conventional sphygmomanometers properly
•	 Replace old sphygmomanometers with validated automatic 
devices
•	 Encourage SBPM and ABPM for clear indications.
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to be focussed on managing individuals with the greatest potential 
to benefit from treatment. Despite the availability of many CVD 
risk factor systems and charts, all have shortcomings, particularly 
in developing countries such as South Africa. Any consensus must 
address topics such as the weighting of BP readings and other risk 
factors in relation to ethnic group, resources, and the development of 
associated clinical conditions (ACC) and TOD. The SAHS remains 
committed to the format of the CVD risk assessment (Table II) until 
there is national consensus on a different model by all stakeholders 
(professionals, providers, government and healthcare funders) that is 
supported by adequate local data. The CVD risk assessment described 
in this guideline was developed by the European Hypertension 
Society and the European Society of Cardiology.7 Absolute risk 
and the continuous risk associated with BP is used in many other 
guidelines.6,8,9 This pragmatic risk assessment model is adaptable 
for use in many settings, including those constrained by limited 
resources and low budgets.
There is consensus on the necessity of immediate drug treatment 
for those with known ACC and/or TOD and/or a SBP ≥180 mmHg 
or DBP ≥110 mmHg (Fig. 1).7 In the absence of ACC, TOD and very 
high levels of BP, the exact BP level at which to initiate treatment 
has changed over time, and remains the subject of debate. 
4.2 Risk factors, TOD and ACC
Table III lists the major risk factors, ACC and TOD. Modifiable 
risk factors (e.g. smoking and dyslipidaemia) should be the target 
of lifestyle intervention and treatment as appropriate. In addition 
to controlling hypertension, TOD and ACC must be managed 
appropriately and, if necessary, the patient must be referred to a 
higher level of care.
Consensus is lacking in treatment decisions on the importance 
of newer risk factors such as obesity and the metabolic syndrome, 
e.g. obesity may be measured using the body mass index (BMI), 
abdominal circumference or waist-to-hip ratio.24 The metabolic 
syndrome has not been listed as a risk factor as in the JNC 7 report, 
despite evidence of its link to CV risk and future diabetes.5 The 
Table I. Different methods of BP measurement* 
Clinic Home Ambulatory
Predicts outcome? Yes Yes Strongly
Initial diagnosis? Yes Yes Yes
Cut-off BP levels (mmHg) 140/90 135/85 135/85 (mean day)
120/70 (mean night)
Evaluation of treatment? Yes Yes Limited but valuable
Assess diurnal rhythm? No No Yes
* The small difference between the clinic BP and the ABP shown, does not clearly reflect an increasing difference between the 2 measurements as the clinic BP rises. As the clinic BP rises, the 
ABP rises much less.22 Thus a clinic BP of 180/110 mmHg corresponds to an ABP of 148/94 mmHg or even 150/95 mmHg. This may result in a large difference of 30/15 mmHg between the 
higher clinic BP levels and the ABP.
Table II. Stratification of risk to quantify prognosis* 
BP (mmHg)
Other risk factors and 
disease history
Normal
SBP 120 - 129
or
DBP 80 - 84
High normal
SBP 130 - 139
or
DBP 85 - 89
Stage 1:
Mild hypertension
SBP 140 - 159
or
DBP 90 - 99
Stage 2:
Moderate 
hypertension
SBP 160 - 179
or
DBP 100 - 109
Stage 3:
Severe hypertension
SBP >180
or
DBP >110
No other major risk factors Average risk Average risk Low added risk Moderate added risk High added risk
1 - 2 major risk factors Low added risk Low added risk Moderate added risk Moderate added risk Very high added risk
≥3 major risk factors or 
TOD or diabetes mellitus 
or metabolic syndrome
Moderate added risk High added risk High added risk High added risk Very high added risk
ACC High added risk Very high added risk Very high added risk Very high added risk Very high added risk
* Based on the ESH/ESC guidelines.7
Fig. 1. Southern African hypertension management flow diagram based on 
added CVD risk (adapted from the WHO CVD risk-management package 
for low - medium resource settings).
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STRATIFY ACCORDING TO ADDED RISK (as in risk chart Table II)  
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Monitor BP & other risk 
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LIFESTYLE MODIFICATION AS APPROPRIATE 
Monitor BP & other risk 
factors for 3 – 6 months 
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syndrome represents a combination of underlying and major risk 
factors; however, there is debate as to which criteria to adopt and 
whether the clustering of risk factors represents a greater CV risk over 
and above the individual components used in the Framingham risk 
calculation. However, where the metabolic syndrome is present, a SBP 
in ≥140 mmHg and or DBP ≥85 mmHg requires treatment (weight 
loss and exercise followed by drug therapy, after an appropriate trial 
of lifestyle modification). Table IV shows the new definition of the 
metabolic syndrome,25 which has recently harmonised with other 
major international bodies.26
4.3 Routine baseline investigations
Table V lists recommended routine basic investigations. Apart from 
measurements of overweight and obesity, the tests are performed 
annually, unless abnormal results are obtained. Tests with abnormal 
results must be repeated as clinically indicated.
5. Goals of BP-lowering treatment
The goals of BP-lowering treatment vary according to number 
of major risk factors, TOD and/or ACC (Table VI). These goals 
should be added to the recommended goals for waist/abdominal 
circumference, blood sugar and lipid levels in patients with the 
metabolic syndrome (section 8.3).
6. Sustainable hypertension 
management and scarce resources
The Hypertension Working Group has given considerable time, 
thought and debate to the concerns about the economic sustainability 
of lifelong drug therapy. Affordability is important in South Africa’s 
private and public sectors. This becomes more relevant given 
the proposals for the holistic management of hypertension, its 
complications and disease associations (section 8.3).
SAHS strongly reiterates the importance of lifestyle modification 
at all stages of hypertension. If resources are limited, drug treatment 
may be delayed if the added CV risk is low or moderate (Table II and 
Fig. 1). Studies emphasise the cost-effectiveness of lifestyle and drug 
management in reducing CVD risk in developed and less-developed 
regions of the world, and the importance of tight BP control in 
African-Americans. 
Currently, the price of antihypertensive and other drugs 
fluctuates considerably irrespective of market sector. Where 
possible, generic equivalents and combinations are encouraged 
and the cheapest generic in a class should be considered, 
provided that it is a true equivalent. The patient should not be 
changed frequently from one generic to another in the same 
Table III. Major risk factors, target organ damage (TOD) and associated clinical conditions (ACC)*
Major risk factors TOD ACC
Levels of SBP and DBP LVH: based on ECG CHD
Smoking Sokolow-Lyon >38 mm HF
Dyslipidaemia Cornell >2440 mm.ms CKD
Total cholesterol >5.1 mmol/l,  OR Microalbuminuria albuminuria >30 mg/mmol, OR
LDL >3 mmol/l, OR albumin creatine ratio 3 - 30 mg/mmol creatinine >133 µmol/l (men)
HDL <1 (men) and <1.2 mmol/l (women) Slightly elevated creatinine: creatinine >124 µmol/l (women) 
Diabetes mellitus 115 - 133 µmol/l (men) Stroke or TIA
Men >55 years 107 - 124 µmol/l (women) Peripheral arterial disease
Women >65 years Advanced retinopathy:
Family history of early-onset CVD Haemorrhages, OR
Men aged <55 years Exudates
Women aged <65 years Papilloedema
Waist circumference  
Men ≥94 cm
Women ≥80 cm 
 Exceptions are South Asians and Chinese: 
Men >90 cm and women >80 cm
* Adapted from the ESH/ESC guidelines.7
Table IV. International Diabetes Federation (IDF)  
definition of metabolic syndrome26
According to the new IDF definition*, a person is defined as 
having diabetes if they have at least 3 of the following criteria:
•	  Central obesity: defined as waist circumference >94 
cm for white men and ≥80 cm for white women with 
ethnicity-specific values for other groups
•	  Raised TG level: ≥1.7 mmol/l, or specific treatment for 
this lipid abnormality
•	  Reduced HDL cholesterol: <1.03 mmol/l in males and 
<1.29 mmol/l in females, or specific treatment for this 
lipid abnormality
•	  Raised BP: SBP ≥130 mm Hg or SBP ≥85 mmHg, or 
treatment of previously diagnosed hypertension
•	  Raised fasting plasma glucose (FPG) ≥5.6 mmol/l, or 
previously diagnosed Type 2 diabetes; an oral glucose 
tolerance test (GTT) is strongly recommended but is not 
necessary to define presence of the syndrome.
*The definition has been updated from those originally presented to ensure consistency 
with Adult Treatment Panel III (ATPIII) criteria.25
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class, solely because of lower price. SAHS is concerned that 
guidelines overemphasise the use of limited resources (when to 
introduce medication, use of generics, and inadequate level of 
BP control) and may lead to poorly managed hypertension with 
the undesirable consequences of heart failure, stroke and chronic 
renal failure. Best practice recommendations should be stated 
clearly and compromises, based on limited resources, should be 
made deliberately and transparently.
7. Management
A diagnosis of hypertension may be made if repeat BP measurements, 
performed on 3 separate occasions within a period of 2 months, 
indicate a SBP ≥140 mmHg and/or a DBP ≥90 mmHg. Where 
circumstances permit, ABPM should be considered, particularly in 
the absence of TOD. This section does not apply if the SBP is ≥180 
mmHg or the DBP is ≥110 mmHg: refer to section 9 on severe (stage 
III) hypertension. 
Lifestyle information should be given to all patients when BP 
measurement is performed. In the case of elevated BP, a programme 
of lifestyle modification should be implemented immediately (Fig. 1 
and section 8 – further clarified by using Table II).
7.1 Lifestyle modification
A healthy lifestyle remains the cornerstone of managing hypertension 
regardless of BP level: in addition to decreasing BP, it enhances 
antihypertensive drug efficiency and decreases total CV risk. The 
Department of Health’s strategy for a healthy lifestyle is supported – 
measures to improve BP include (Table VII):
Table V. Routine investigations
Investigation Clinic frequency Comments
Body weight / overweight 
Body weight Every visit
Height First visit
BMI Every visit <25 kg/m2 for men and women (refer to Table 
IX for definitions of obesity)
Abdominal obesity
Waist circumference Every visit Use correct method of measurement 
Men <94 cm and women <80 cm; South Asians 
and Chinese: men <90 cm and women <80 cm
OR
Waist-to-hip ratio The waist-to-hip ratio has greater predictive 
value than BMI or waist circumference for MI 
but may not be practical in many settings
Urine dipstick 
Protein First visit Abnormal dipstick – any one of the following:
Blood Yearly if normal •	 Proteinuria ≥2+
Sugar Repeat at next visit if abnormal on first visit •	 Haematuria ≥1+
Refer for immediate further investigation
Microalbuminuria
 Diabetes mellitus and selected hypertensives 
only
First visit then yearly Performed on diagnosis of diabetes mellitus 
Type 2, or 5 years after diagnosis of Type 1; 
refer to the SAHS policy on microalbuminuria
Blood tests
Creatinine Yearly if normal From serum creatinine calculate GFR 
(modified MDRD equation = GFR in  
ml/min/1.73 m²)
Potassium Yearly if normal
Glucose (fasting preferred) Yearly if normal Consider GTT in patients with fasting glucose 
>6.1 mmol/l
Random total cholesterol Yearly if normal Measure fasting lipogram if cholesterol  
>5.1 mmol/l or in high-risk groups
ECG (resting) Yearly if normal Refer to SAHS policy brief on LVH
Secondary cause suspected Referral as necessary If suspected at first visit or if refractory 
hypertension exists, additional investigations 
should be performed
If invasive renal, vascular or endocrine 
investigations are required, refer the patient to 
the appropriate specialist or subspecialist
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•	 Achieving and maintaining ideal weight (BMI of 18.5 - 24.9) – 
refer to the 2 local guidelines for the prevention and management 
of obesity.
•	 Limiting total sodium intake to <2 400 mg/day (<1 teaspoon 
of salt). High sodium levels are found not only in table salt, but 
also in packet soups, stock cubes, gravies, processed cheese, many 
breakfast cereals, breads, salty snacks and tinned foods. Reducing 
the intake of such foods is crucial. The removal of the salt cellar 
from the table and a gradual reduction in added salt in food 
preparation should be recommended. Patients must be informed 
that food may taste bland initially and that taste adaptation to 
reduced sodium intake occurs with time; the use of lemon juice, 
herbs and spices as alternative seasoning should be encouraged. 
Salt content is listed as sodium in food labels:
•			‘Sodium	free’:	<5	mg	per	100	g	serving
•			‘Very	low	sodium’:	≤40	mg	per	100	g	serving
•			‘Low	sodium’:	≤120	mg	per	100	g	serving
•				Salt	 content	 can	 be	 calculated	 by	multiplying	 sodium	 content	
by 2.5.
•	 Limiting alcohol intake to 2 standard drinks per day for men and 
1 standard drink per day for women and small men. A standard 
drink (approximately 10 g of ethanol) is equivalent to 25 ml of 
liqueur/spirits, 125 ml of wine, 340 ml of beer, or 60 ml of sherry. 
•	 Following the nutrition guidelines published by the WHO, 
which emphasise: a diet low in total fat with high intake of fruit 
and vegetables (5 portions per day), regular low-fat dairy products, 
high intake of high-fibre wholegrain foods, fish rather than red 
meat, products low in saturated fat, low salt, and sparing use 
of sugar and sugar-containing foods.8,14,17 Beverages with high 
caffeine levels should be avoided, but modest use (1 - 2 cups of 
coffee per day) will not increase BP.
•	 Regular moderate intensity exercise for at least 30 minutes on 
most – preferably all – days of the week, e.g. brisk walking at 40 
- 60% of peak. Exercise bouts can be continuous or accumulated 
in shorter periods throughout the day. The benefit of exercise 
is dose-responsive: early adaptations from a sedentary lifestyle 
to becoming moderately active have the greatest effect. Patients 
with uncontrolled hypertension should only embark on exercise 
training after evaluation and initiation of therapy.
•	 Avoiding the use of all tobacco products, including snuff. 
Nicotine replacement therapy should be used for a patient with 
hypertension, while under medical supervision.
7.2 Drug therapy
In use of these recommendations for treatment, it is essential that 
the patient’s added CV risk is assessed according to Table II, thereby 
informing the decision to implement drug therapy according to 
the decision flow chart (Fig. 1). Drug therapy is commenced in the 
following cases:
•	 Low added risk: SBP remains ≥140 mmHg or DBP remains ≥90 
mmHg despite a period of lifestyle modification and observation 
(6 - 12 months)
•	 Moderate added risk: SBP remains ≥140 mmHg or DBP remains 
≥90 mmHg despite a period of lifestyle modification and 
observation (3 - 6 months)
•	 High or very high added risk.
The following must be considered prior to the selection of an 
antihypertensive agent: the cost of the drug class, patient-related 
factors such as the presence of major risk factors, conditions 
favouring use, contraindications, ACC and TOD (Tables III and 
VIII). In otherwise uncomplicated essential hypertension, there 
are 3 important antihypertensive agents: diuretics (thiazide and 
thiazide-like), angiotensin-converting enzyme inhibitors (ACE-Is) 
and calcium channel blockers (CCBs). A thiazide-like diuretic is 
advisable when consideration for the cost of therapy is relevant. 
Studies have led to reconsideration of the drugs of choice for the 
management of uncomplicated hypertension. The most cost-effective 
antihypertensive drugs are a thiazide-like diuretic (or a CCB in black 
patients).10 The combination of a thiazide diuretic with a β-blocker is 
discouraged, especially where there is abdominal obesity combined 
with hypertension; both classes of drugs have adverse metabolic 
consequences and increase the risk of new diabetes.
In uncomplicated essential hypertension, therapy should be 
initiated with a diuretic, ACE-I (or ARB – angiotensin II receptor 
blocker), or CCB. Combination therapy should be considered ab initio 
if BP is ≥20/10 above goal, with either an ACE-I (or ARB)/diuretic, 
ACE-I/CCB or CCB/diuretic combination. A thiazide-like diuretic 
with a CCB is the preferable combination for black hypertensive 
patients. In general, fixed drug combinations (FDCs) are preferred. 
If control is not reached with monotherapy, combination therapy 
should be instituted with another drug from the first-line classes.
The choice of diuretic should be a low-dose hydrochlorothiazide 
(12.5 - 25 mg) or a thiazide-like diuretic-like indapamide (1.25 - 
2.5 mg daily). Chlorthalidone (15 - 30 mg daily) is more potent 
compared with hydrochlorothiazide; it produces a sustained 24-hour 
BP-lowering response, and may replace hydrochlorothiazide as a 
hypotensive agent.10,27-29 Chlorthalidone is currently not available 
in South Africa, except as a fixed combination with atenolol. Loop 
diuretics such as furosemide should not be used because of their 
short duration of hypotensive activity (about 6 hours), unless there 
is evidence of chronic kidney disease (CKD) with an estimated 
glomerular filtration rate (GFR) <45 ml/min.
Table VIII lists the clinical considerations and possible contra-
indications of the major antihypertensive drug groups. Issues relating 
to drug adherence are critical and must be considered in each patient 
(section 14). Ensuring that each patient understands the importance of 
adherence to the treatment regimen and returns drug containers and 
unused drugs should be reinforced frequently. Patient empowerment 
and single daily dose regimens improve compliance. Fixed-dose 
combinations should be used where appropriate. Continued monitoring 
and management of drug side-effects is essential. 
Hypertension can seldom be managed in isolation from other 
related chronic illnesses. Lifestyle modification, drug therapy and the 
targets of management should be broadened to include measures of 
other risk factors and co-morbidities, e.g. obesity, blood sugar, lipids 
and BP control (Table IX).
The metabolic syndrome is of increasing prevalence. The clinical 
criteria of the syndrome have been debated and may include 
obesity, dyslipidaemia and Type 2 diabetes mellitus in addition 
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Table VI. Goals of BP-lowering treatment
Stage BP level*
All stages <140/90 mmHg
High-risk patients, e.g.: <130/80 mmHg
Diabetes mellitus
 Renal disease 
(microalbuminuria and/or 
elevated creatinine)
Congestive heart failure
* Ideally these targets should be reached within 3 months. 
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to hypertension. This guideline recognises that insulin levels or 
insulin/glucose ratios have no place in the diagnosis (Table IV). The 
syndrome is not a clearly defined entity with an evident aetiology or 
underlying mechanism; therefore, its management should reflect the 
accepted strategies to reduce CV risk, and each component of the 
syndrome should be managed if present (e.g. increased abdominal 
girth and BP is decreased with a combination of intensive diet and 
exercise).
Table VII reflects the current South African norms for the Dietary 
Approaches to Stop Hypertension (DASH).30 A low-sodium diet 
will lower BP and also have a favourable effect on weight, lipids 
and glycaemic control. Evidence is mounting that so-called normal 
lipid levels may be inappropriately high in hypertensive patients, 
and are certainly so in patients with hypertensive complications, 
e.g. stroke and myocardial infarction (MI). Lipid-lowering therapy 
is increasingly becoming a part of standard drug therapy in both 
young and old patients with vascular disease. In some cases, the use 
of the biguanide and/or metformin may be required, in addition to 
exercise, to prevent the progression to frank Type 2 diabetes mellitus 
in hypertensive patients with central obesity.
Questions are frequently asked regarding the indications and 
contraindications for the use of aspirin, hormone replacement 
therapy and antioxidants. Low-dose aspirin should be used for 
secondary prevention of a transient ischaemic attack (TIA), stroke 
and MI, only once the BP is well-controlled. The use of hormone 
replacement therapy, antioxidants, homoeopathic or complementary 
drugs is of no benefit in hypertensive patients.
7.2.1 Consensus statement on the use of ACE-Is and ARBs
The use of ARBs and ACE-Is results in up to 95% and 75% 
blockade, respectively, of the renin-angiotensin system. No 
difference in this outcome was found in patients with diabetes 
and microalbuminuria (N=50)31 or in patients post myocardial 
infarction, with heart failure and/or impaired left ventricle (LV) 
dysfunction.32 The ARB losartan produced greater regression 
of left ventricular hypertrophy (LVH), a 14% reduction in the 
primary end-point of CV morbidity and death, and a 25% 
reduction in stroke, compared with a β-blocker.33 ACE-Is have 
been shown to prevent the progression of microalbuminuria from 
normoalbuminuria, and reduce established microalbuminuria 
in Type 2 diabetes.34 ARBs have also been shown to reduce 
microalbuminuria, and delay the progression of established 
diabetic nephropathy.35 ACE-Is, in combination with indapamide36 
or an ARB, have proven effective in the secondary prevention of 
stroke.37 Furthermore, the effect of the ARB, telmisartan, has been 
shown to be equivalent to that of the ACE-I, ramipril, in patients 
at high CV risk. Combination therapy, however, had no added 
advantage, and caused increased side-effects and adverse renal 
outcomes.38 Hence, there appears to be little difference between 
ACE-Is and ARBs; choice of therapy should be determined by cost 
and tolerability.31
7.2.2 Compelling indications for a specific drug class
Table VIII outlines the compelling indications (high-risk conditions) 
for certain classes of antihypertensive drugs, based on randomised 
Table VII. Lifestyle modification for hypertension care.
Modification Recommendation Approximate SBP reduction
Weight reduction Maintain normal body weight (BMI*; 18.5 - 24.9) by 
means of limited calorie intake and adequate daily 
physical activity
5 - 20  mmHg/10 kg weight loss
Dietary sodium reduction Reduce	dietary	sodium	intake	to	≤100	mEq/l 2 - 8  mmHg
(2.4 g sodium or 6 g sodium chloride - limit salt intake)
Moderate alcohol consumption Limit consumption to no more than 2 standard drinks per 
day in men and 1 standard drink per day in women
2 - 4  mmHg
Limit total fat intake (according to the WHO, 
total fat intake should be 15 - 30% of total 
energy) 
Limit total fat intake, reduce saturated and trans-fatty 
acids
Recommended maximum fat intake for moderately active 
adults:
Female normal weight = 70 g/day
Female overweight = 50 g/day
Male normal weight = 95 g/day
Male overweight = 70 g/day
Increase fruit and vegetable consumption Increase fruit, vegetables, legumes, whole grains and nuts 
to 5 helpings per day
Limit free sugars Reduce free sugars to less than 40 g/day (8 level 
teaspoons)
Physical activity Engage in regular aerobic physical activity such as brisk 
walking at least 30 min/day, most days of the week, 
minimum of 150 min/week
4 - 9  mmHg
Stop smoking and  ALL nicotine-based products
* BMI = weight (kg) divided by the square of height (m2).
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Table VIII. Indications and contraindications for the major classes of antihypertensive drugs* 
Class Conditions favouring use
Contraindications
Compelling Possible
Diuretics HF Gout Pregnancy
(thiazide/thiazide-like) Elderly hypertensives β-blockers (especially atenolol)
ISH
Hypertensives of African origin
Diuretics Renal insufficiency Pregnancy
(loop) HF
Diuretics HF Renal failure
(anti-aldosterone) Post-myocardial infarction Hyperkalaemia
Resistant hypertension
CCB Elderly patients Tachyarrhythmias
long-acting only (dihydropyridine) ISH HF
Angina pectoris
Peripheral vascular disease
Carotid atherosclerosis
Pregnancy (nifedipine only)
Non-dihydropyridine Angina pectoris AV block (grade 2 or 3) Constipation (verapamil)
CCB Carotid atherosclerosis HF
(verapamil, diltiazem) Supraventricular tachycardia
ACE-Is HF Pregnancy
LV dysfunction Hyperkalaemia
Post-myocardial infarction Bilateral renal artery stenosis
Non-diabetic nephropathy Angioneurotic oedema (more
common in blacks than in whites)Type 1 diabetic nephropathy
Prevention of diabetic 
microalbuminuria
Proteinuria
ARBs Type 2 diabetic nephropathy Pregnancy
Type 2 diabetic 
microalbuminuria
Hyperkalaemia
Non-diabetic nephropathy Bilateral renal artery stenosis
LVH
ACE-I cough or intolerance
Patients at high CV risk
β-blockers Angina pectoris Asthma Peripheral vascular disease
Post-myocardial infarction Chronic obstructive pulmonary 
disease
Bradycardia
HF (selected) Glucose intolerance
Tachyarrhythmias AV block (grade 2 or 3) Metabolic syndrome
Pregnancy (atenolol) Athletes and physically active 
patients
Non-dihydropyridine CCBs 
(verapamil, diltiazem)
* Adapted from the JNC7 guidelines.5
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controlled trials. These indications apply equally to patients from any 
ethnic group; however, the prevalence of other illnesses such as diabetes 
in certain groups such as the Asians must be considered (section 11.1).
7.2.3 Direct renin inhibitor
Since the last guideline publication, the direct renin inhibitor, 
aliskiren, has been registered for the treatment of hypertension in 
the USA and Europe. This drug provides antihypertensive efficacy 
similar to other classes of drugs and has a similar placebo-like profile 
to ARBs. It can be combined effectively with other major classes of 
antihypertensive drugs, especially diuretics and CCBs. In the absence 
of major outcome studies, the place of direct renin inhibitors is not 
established and it is uncertain whether aliskiren will have additional 
benefits over ACE-Is and ARBs. However, benefits of the combination 
of aliskiren with ACE-Is and ARBs have been shown in patients with 
diabetic nephropathy and heart failure, respectively.39,40 Long-term 
outcome studies – such as the ALTITUDE study in patients with Type 
2 diabetic nephropathy41 – are awaited before recommendations on 
the use of direct renin inhibitors can be made.
7.2.4 New trials
Seven recent trials, involving 83 112 patients with hypertension 
and other co-morbidities, have been published and have influenced 
this guideline: TRANSCEND,42 ON TARGET,38 ACCOMPLISH,43 
HYVET,44 PROFESS,45 AVOID,39 ADVANCE,46 and ACCORD.47 
Prior to the HYVET study, the treatment of hypertension in very 
elderly patients was not proven to be beneficial; the study showed 
unequivocally that initiation of treatment with indapamide, with or 
without perindopril vs. placebo, resulted in significant reductions in 
mortality and CV end-points.44 
The ACCOMPLISH study demonstrated that combination 
treatment with amlodipine plus benazepril vs. hydrochlorothiazide 
plus benazepril resulted in a 20% reduction in the primary end-
point.43 This influenced the recent ISHIB guidelines regarding 
combination therapy, where a CCB plus RAAS inhibitor combination 
was preferred, except in the event of volume overload.48 In the latter 
case, a RAAS inhibitor plus diuretic combination was preferred.
Two recent studies in Type 2 diabetes showed contrasting results. 
In the ADVANCE study, the addition of perindopril plus indapamide 
Table IX. Current South African norms for dyslipidaemia, obesity and diabetes
Lipid and triglyceride goals 
Lipid Current recommended SA levels for different levels of risk
Established CVD, diabetes TC <4.5 mmol/l
OR Triglyceride <1.7 mmol/l
High CVD risk HDL-C men >1 and women >1.2
LDL-C* <2.5
Intermediate TC <5 mmol/l
OR Triglyceride <1.7 mmol/l
Low CVD risk HDL-C >1 men >1.2 women
LDL-C* <3
Obesity BMI
Classification BMI (kg/m²) Risk of chronic, non-communicable diseases
Underweight <18.5† Low (but risk of other clinical problems may be greater)
Normal weight 18.5 - 24.9 Average
Pre-obese (overweight) 25.0 - 29.9 Increased
Obese (class I) 30.0 - 34.9 Moderate
Obese (class II) 35.0 - 39.9 Severe
Obese (class III) ≥40.0 Very severe
Abdominal obesity waist circumference
Ideal Substantial risk
Men <94 cm >102 cm
Women <80 cm >88 cm
 
Symptoms of diabetes PLUS
•	 casual plasma glucose concentration ≥11.1 mmol/l,‡ OR
•	 fasting plasma glucose ≥7.0 mmol/l,§ OR 
•	 2 h post-prandial glucose ≥11.1 mmol/l during an oral glucose tolerance test. 
* LDL-C is the primary target of treatment;
† Values are considered to be independent of age, and are the same for men and women;
‡ Casual is defined as any time of day without regard to time since the last meal. The classic symptoms of diabetes include polyuria, polydipsia and unexplained weight loss;
§ Fasting is defined as no calorie intake for at least 8 hours; 
¶ The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water;
Note: In the absence of unequivocal hyperglycaemia with acute metabolic decompensation, these criteria should be confirmed by repeat testing on a different day. The oral glucose tolerance 
test (OGTT) is not recommended for routine clinical use but as many as 30% of people with diabetes will not be diagnosed if only fasting measurements are done. Different criteria are used to 
diagnose gestational diabetes in pregnant women. 
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vs. placebo resulted in significant reductions in both macro- and 
microvascular complications, with no lower threshold for BP.46 In 
contrast, in the ACCORD study, intensive (<120/80 mmHg) vs. 
standard care did not result in a reduction in the primary end-point 
of CV morbidity and mortality, but did reduce the secondary end-
point of stroke.48 These contrasting results have created a dilemma 
regarding the target BP in diabetics.
The PROFESS45and TRANSCEND42 studies showed no reduction 
in the primary end-point in patients with a previous stroke or those 
at high CV risk and intolerant to ACE-Is, despite significant lowering 
of the BP. This has prompted a re-evaluation of lower BP targets for 
patients at higher CV risk. Studies of a larger scale and longer time-
frame may be required to demonstrate unequivocal benefit.
7.2.5 Combination treatment in hypertension
The pathophysiology of hypertension is multifactorial. Data show 
that the reductions in BP produced by monotherapy are too small to 
achieve recommended BP targets. The use of combination therapy 
is recommended, especially if the BP >20/10 mmHg above goal and 
there are co-morbidities to consider such as diabetes, ISH, CKD or 
overt CVD. There is a revival of combination therapy owing to poor 
BP control in different countries and the need to achieve lower target 
BP levels. 
Combination therapy may include free or fixed combination of a 
standard or lower dose. BP reduction with a low-dose combination 
of agents is comparable to that achieved with full-dose single agents, 
with a lower incidence of side-effects. FDC can be defined as 2 or 
more drugs in a single formulation, with independent modes of 
action, the combination of which is synergistic or complementary 
in effect. Free combinations can be defined as 2 or more drugs 
in separate formulations, usually taken at the same time. The 
requirement for a rational fixed-dose antihypertensive combination is 
that each component should be safe, efficacious, and have predictable 
pharmacokinetic and pharmacodynamic profiles, with a high trough-
peak ratio and no excessive hypotensive episodes. 
The benefits of combination therapy include an enhanced 
antihypertensive effect, better response rates and outcomes, and 
fewer adverse effects. Effective drug combinations include diuretics 
with β-blockers, diuretics with long-acting CCBs, ACE-Is or ARBs, 
and β- and α-blockers. Black patients respond best to diuretics or 
CCBs combined with other antihypertensive agents. Drug synergism 
exists with ACE-Is or ARBs combined with either CCBs or diuretics. 
Synergism is defined as a co-operative action resulting in a total effect 
that is greater than the sum of the effects taken individually; this may 
relate to BP and TOD. 
7.3 Fixed drug combinations in hypertension and 
hyperlipidaemia
In many developing countries, the primary problem to be addressed 
with FDC therapy is not incomplete treatment, but rather the lack 
of treatment in patients unknown to the healthcare system. In this 
setting, the benefits of FDCs would be derived primarily from 
simplifying the process of patient identification and treatment 
provision. 
There is limited empirical evidence to support or refute the main 
purported advantage of FDC, namely increased patient adherence.49 
Additional presumed advantages include: (i) a simpler dosage 
schedule which improves compliance and treatment outcomes; (ii) 
a reduction in inadvertent medication errors; (iii) reduced drug 
shortages, i.e. simplification of drug handling lowers the risk of 
being ‘out of stock’; (iv) simplified drug procurement, management 
and handling; (v) lower production, packing and shipping costs; and 
(vi) reduced side-effects, if one of the combined drugs serves this 
purpose.50 The presumed disadvantages of FDCs include: (i) a greater 
expense than separate tablets, although not invariably so; (ii) cases 
where FDC therapy must be discontinued and replaced by separate 
tablets if a patient is allergic or has side-effects (this also applies with 
single-dose formulations); and (iii) irrational combinations may 
result from incompatible pharmacokinetics, i.e. different elimination 
half-lives of individual components.50 
The pharmaceutical industry, academic and public health sectors 
advocate the expansion of secondary CVD prevention. A proposed 
FDC for established ischaemic heart disease is aspirin 75 mg, 
simvastatin 10 mg, lisinopril 10 mg and atenolol 25 mg daily, and for 
established ischaemic cerebrovascular disease a combination of aspirin 
75 mg, lisinopril 10 mg, simvastatin 10 mg and hydrochlorothiazide 
12.5 mg daily51. All of these drugs are available in generic formulation.
The polypill holds promise for the treatment of chronic disease.51-53 
Although the value of such a pill remains to be ‘clearly demonstrated 
rather than simply assumed’, a 3 - 4 drug polypill has been supported 
by the World Health Organization53,54 and a global trial began in 2007. 
Only 20% of chronic diseases occur in high-income countries; 80% 
occur in low- and middle-income countries, with equal numbers 
of deaths in men and women.52 High-cost physician models of care 
for chronic diseases are unsuitable in the latter. It has been shown 
that 20% of patients with coronary heart disease (CHD) in such 
countries were not receiving any aspirin, and patients requiring 
β-blockers – which are low-cost and widely available – were not 
receiving them.53 This has been one reason to introduce the polypill, 
and it will hopefully improve compliance; however, Reddy feels that 
the ‘preventive polypill has much promise but insufficient evidence’.54
7.4 Antihypertensive drug interactions
A drug interaction is the quantitative modification of drug effect by 
the simultaneous or successive administration of a different drug. 
Antihypertensive agents have many drug interactions, some of which 
are highly significant; morbidity or mortality can result if steps are 
not taken to minimise this risk. Patients with hypertension frequently 
take multiple medications and are therefore at increased risk of drug 
interactions. There is also significant potential for drug interactions 
in the elderly, as they often receive larger number of drugs and show 
renal impairment in the excretion of several therapeutic agents. 
Drug interactions may occur via pharmacokinetic (i.e. absorption, 
distribution, metabolism, and elimination) or pharmacodynamic 
means. The most frequent interactions related to clinical problems 
are pharmacokinetic; most stem from metabolism via the cytochrome 
P450 system or presystemic clearance by means of P-glycoprotein. 
Polymorphisms of the cytochrome P450 enzymes may explain the 
individual differences or the appearance of drug interactions. Certain 
drugs may impair the renal excretion of other agents, usually at 
the tubular level, e.g. drug plasma level and toxicity increases have 
been demonstrated with concomitant use of verapamil, amiodarone 
or quinidine.55 Of the statins, simvastatin is particularly prone to 
drug interactions, partly because it is extensively metabolised by 
the cytochrome CYP3A4 enzyme system.55 The SEARCH trial 
indicated that much of the increase in risk for myopathy noted in 
the high-dose simvastatin group was due to the concomitant use 
of medications such as amiodarone, diltiazem and amlodipine.56 
Judicious concomitant use of other medications with simvastatin will 
reduce the risk of myopathy (Table X). 
There may be pharmacodynamic interactions between similarly 
acting drugs which may lead to additive or potentiation effects, e.g. 
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Table X. Interactions between antihypertensives and other drugs55
Drugs (Class) Interaction with Mechanism Effect
β-blockers Verapamil, diltiazem Additive effects A-V conduction impaired: risk of 
A-V block
Oral antidiabetics b2-receptor blockade Symptoms of hypoglycaemia are 
suppressed
Broncho-spasmodic agents b2-receptor blockade Suppression of the broncho-
spasmolytic effect
Dobutamine b1-receptor antagonism The intropic action of 
dobutamine is inhibited
Thiazide diuretics Digoxin Hypokalaemia Digoxin become more toxic 
(arrhythmogenic)
Lithium ions Renal excretion of lithium ions 
impaired
Accumulation of lithium ions
α-blockers Noradrenaline a1-receptor blockade Noradrenaline shows less 
vasoconstrictor activity
Calcium antagonists
Verapamil, diltiazem β-blocker Additive effect A-V conduction impaired; risk of 
A-V block
Digoxin Renal excretion of digoxin Digoxin may accumulate, 
arrythmogenic effect
Protease inhibitors (HIV-
treatment)
Inhibition of hepatic degradation Accumulation of verapamil or 
diltiazem
Dihydropyridine β-blocker β-receptor blockage Suppression of reflex tachycardia 
(favourable)
Felodipine Grapefruit juice Enzymic inhibition (Cytochrome 
P450 system)
Accumulation of felodipine
Amlodipine Simvastatin >20 mg daily Simvastatin is extensively 
metabolised by the CYP3A4 
enzyme system
Increased risk for myopathy
Diltiazem, amiodarone Simvastatin > 10 mg daily Simvastatin is extensively 
metabolised by the CYP3A4 
enzyme system
Increased risk for myopathy
ACE-Is Diuretics (thiazide) Additive effect Enhanced hypotensive action
Diuretics (K+-sparing) Reduced renal excretion of K+ Hyperkalaemia
NSAIDs including high-dose 
salicylates
Retention of Na+ and H2O, 
hyperkalaemia
Reduced antihypertensive effects
Lithium ions Reduced excretion of lithium ions Lithium ions accumulate
AT1-receptor antagonists Virtually the same as ACE-Is Interactions as ACE-Is (see 
above)
Described before
Drugs Mechanism of action Increase in BP
Interferes with antihypertensive 
effect
Sympathomimetics Nasal decongestants (α-receptor) Yes No
Ergot alkaloids Antimigraine drugs, 
bronchodilators (β2-receptor)
Yes No
NSAIDs Sodium retention, inhibition of 
vasodilating prostaglandins
Yes Yes
Oral contraceptives Oestrogens and progesterone Yes No
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the combination of intravenous verapamil and a β-blocker may cause 
additive impairment of a cardiac atrioventricular (AV) block. A 
combination of 2 or more antihypertensive agents may be expected to 
cause an additive BP-lowering effect. The antidepressant effects of all 
drugs that suppress the activity of the central nervous system enhance 
the side-effects of centrally acting antihypertensives (reserpine, 
α-methyldopa, guanfacine and clonidine). Recently, attention has 
been paid to the interaction of antihypertensives and non-steroidal 
anti-inflammatory drugs (NSAIDs).55 The ONTARGET study 
showed that telmisartan was as effective as ramipril, with marginally 
increased tolerability. The combination of the two was not superior 
to ramipril and had increased side-effects; the data suggest that the 
combination could precipitate acute renal failure and aggravate the 
onset of renal insufficiency.38 A summary of drug interactions in 
hypertension is shown in Table X.55 
8. Management of severe hypertension
Severe hypertension (stage 3 DBP ≥110 mmHg and/or SBP ≥180 
mmHg) may be classified into one of 3 categories to determine the 
urgency of treatment, namely asymptomatic severe hypertension, 
hypertensive urgency and hypertensive emergency. Patients should 
be managed or referred to the appropriate level of care in accordance 
with local protocols. Sustained severe hypertension requires 
immediate drug therapy and lifestyle modification.
8.1 Asymptomatic severe hypertension
These patients are asymptomatic but have severe hypertension with 
or without evidence of progressive TOD or ACC. The patient must 
be kept in the care setting and BP measurement must be repeated 
after 1 hour of rest. If the second measurement remains elevated at 
the same level, oral therapy should be started with a combination of 
2 drugs, including a low-dose thiazide-like diuretic. The second drug 
is usually a dihydropyridine CCB. Follow-up should occur within 
a week, with escalation of treatment as required. Early referral is 
advised if BP is not controlled within 2 - 4 weeks.
8.2 Hypertensive urgencies and emergencies57
Despite advances in chronic hypertension management, hypertensive 
emergencies and urgencies remain serious complications. Factors for 
this include poor compliance with antihypertensive management, 
failure to institute effective antihypertensive therapy, failure to 
refer patients with resistant hypertension timeously, and failure to 
recognise important secondary causes. 
Hypertensive emergencies and urgencies also occur in hypertension 
in pregnancy and in the preoperative period. Many classes of intravenous 
antihypertensive drugs are available to treat hypertensive emergencies, 
and specific agents may have an advantage in a given clinical situation. 
Orally active agents are used to treat hypertensive urgencies and include 
ACE-Is, CCBs, diuretics, α-β-blockers and β-blockers. Most patients 
respond well to drug therapy, but problems may arise if BP is 
normalised rapidly.
Hypertensive emergencies and urgencies are uncommon, but 
are likely to be encountered by all clinicians because of the high 
prevalence of chronic hypertension. All doctors must be familiar 
with treatment. Information is available from well-conducted studies 
on the outcomes of various antihypertensive drugs and BP-lowering 
strategies; therefore, any recommendation is based on case studies, 
clinical reports, comparative studies and expert opinion.
8.2.1 Hypertensive urgency58
Hypertensive urgency is symptomatic, usually with severe headache, 
shortness of breath and oedema. There are no immediate life-
threatening neurological, renal, eye or cardiac complications as 
in the case of hypertensive emergency (section 8.2.2). Ideally, all 
patients with hypertensive urgency should be treated in hospital. 
Treatment should be commenced with 2 oral agents with an aim to 
lower the DBP to 100 mmHg, slowly over 48 - 72 hours. Lowering 
of the BP can be achieved with the use of: (i) long-acting CCBs; 
(ii) ACE-Is used initially in very low doses and avoided if there 
is severe hyponatraemia (serum sodium <130 mmol/l indicates 
hyper-reninaemia and BP may fall dramatically with ACE-Is); (iii) 
β-blockers; and (iv) diuretics (which may potentiate the effects of the 
other classes of drugs). Furosemide should be used if there is renal 
insufficiency or evidence of pulmonary congestion.
8.2.2 Hypertensive emergency
A hypertensive emergency exists when acute elevation of BP is 
associated with acute and ongoing organ damage to the kidneys, 
brain, heart, eyes (grade 3 or 4 retinopathy) or vascular system. Such 
patients require rapid lowering of the BP to safe levels, within minutes 
or a few hours. Once a genuine hypertensive emergency is identified, 
immediate hospitalisation is essential, with monitoring in a modern-
facility intensive care unit (ICU) with experienced staff. Standard 
care includes intravenous antihypertensive therapy tailored to the 
specific type of emergency (except in stroke patients – see ‘Summary: 
management of acute stroke’). The potential threat of harm from 
overzealous lowering of BP exists together with the need for careful 
and structured BP reduction.
The definition of a hypertensive emergency does not explicitly 
include absolute BP levels, although most affected adults have a SBP 
Table X. Interactions between antihypertensives and other drugs55 – continued
Drugs Mechanism of action Increase in BP
Interferes with antihypertensive 
effect
Corticosteroids Sodium retention Yes Yes
Psychotropes
Chlorpromazine, tricyclics, 
Monoamine-oxidase-inhibitors, 
etc Yes No
Erythropoietin Increase in blood viscosity Yes No
Cyclosporine Hypothethical (via nitric oxide) Yes No
Resin Inhibition of GI absorption of 
antihypertension drugs
Yes Yes
Anabolic steroids Sodium retention Yes No
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>220 mmHg and/or DBP >130 mmHg. Hypertensive emergencies may 
also occur at modest BP elevations, e.g. in previously normotensive 
women during pregnancy (eclampsia) or in acute glomerulonephritis 
(especially in children). Hypertensive emergencies are uncommon, 
with an estimated occurrence of less than 1 - 2% of the hypertensive 
population; however, they are more common in black and older 
patients. Most patients know that they are hypertensive, and are 
receiving treatment.
Hypertensive emergencies and urgencies may be seen in the 
immediate postoperative period following vascular surgery. The 
initiating factors of hypertensive emergencies are poorly understood, 
but a rapid rise in BP associated with increased vascular resistance 
is suspected as the initial derangement. Smoking – possibly via 
associated endothelial injury – is suspected to be a risk factor: 
smokers have 5 times the risk of developing malignant hypertension. 
Hypertensive emergencies in patients with thrombotic (ischaemic) 
stroke and intracerebral haemorrhage should be managed according 
to the guideline of the Neurological Association of South Africa.59 
Common clinical hypertensive emergencies are described in 
sections 8.2.2.1 - 8.2.2.4 below.
8.2.2.1 Acute cerebrovascular syndromes
Severe hypertension is common in the case of acute stroke; it is 
debatable whether or not it should be treated, and if so, to which 
immediate target BP. In this setting, cerebral auto-regulation is 
impaired, and rapid BP reduction may result in an ischaemic 
stroke extension. The American Heart Association recommends the 
treatment of hypertension in the case of intracerebral bleeding when 
BP >180/105 mmHg, and the maintenance of mean arterial pressure 
(DBP plus one third of pulse pressure) above 130 mmHg. In the case 
of ischaemic stroke, BP should be observed for at least 1 - 2 hours 
to assess whether it will lessen spontaneously. Only a persistently 
elevated DBP >120 mmHg or SBP >220 mmHg should be treated, 
with caution and an initial 20% reduction in mean arterial pressure.
Hypertensive encephalopathy is a cerebrovascular hypertensive 
emergency characterised by diffuse cerebral dysfunction with headache, 
nausea, vomiting, disturbed consciousness and – rarely – seizures. The 
condition is frequently accompanied by retinal findings of malignant 
hypertension and acute renal dysfunction. Computed tomography 
(CT) imaging usually appears normal with the condition, but may 
show diffuse cerebral oedema or posterior leuko-encephalopathy. The 
gradual lowering of BP generally leads to a fairly rapid improvement 
in symptoms. Sodium nitroprusside or labetalol are recommended 
for treatment. In patients failing to improve within 6 - 12 hours of BP 
reduction, an aggressive additional evaluation should be prompted for 
an alternative cause of the encephalopathy.
8.2.2.2 Acute cardiac syndromes
Severe hypertension in the setting of acute myocardial infarction, 
unstable angina, or pulmonary oedema should be treated aggressively 
and concurrently with all other indicated interventions. BP treatment 
reduces the ischaemic load on the left ventricle. Classic studies have 
shown that treatment with intravenous nitroglycerine is ideal in 
this setting, because it reduces myocardial oxygen consumption and 
increases blood flow beyond a stenosis. Sodium nitroprusside is also 
suitable and can be used alone or in combination with nitroglycerine.
8.2.2.3 Postoperative hypertension60 
Postoperative hypertension is frequent (20 - 75%) and tends to 
be more prevalent in patients with poor pre-operative BP control, 
autonomic disorders, or a history of acute alcohol or cocaine use. 
Reversible causes of the hypertension may include pain, hypoxia, 
a full bladder, hyper- and hypovolaemia, persistent vomiting and 
anxiety. Patients with true emergencies should preferably be treated 
by an appropriate specialist, with admission of the patient to the 
ICU for parenteral drug therapy (Table XI) and monitoring. The 
BP should not be lowered by >25% within 30 - 120 minutes, with a 
goal of 160/100 mmHg within the following 2 - 6 hours. This may be 
achieved with the use of intravenous or oral drugs. 
8.2.2.4 Resistant hypertension 
Refractory or resistant hypertension remains >140/90 mmHg 
despite the use of 3 antihypertensive drugs in a rational full-dose 
combination with a diuretic component. An appropriate therapeutic 
plan must include lifestyle modification measures. In older patients 
with ISH, refractory hypertension is diagnosed when triple therapy 
(as above) has failed to control the BP below 160/90 mmHg. Table XII 
lists the causes of refractory hypertension in South Africa that must 
be considered in management of this condition.
The most common cause of resistant hypertension in South 
Africa is probably non-compliance (adherence) with lifestyle and 
medication; this includes the unavailability of medication and other 
drug-related causes. Unsuspected causes of secondary hypertension 
are less common, but bilateral renal disease and bilateral adrenal 
hyperplasia should be considered. These are suspected in patients 
with a reduced GFR and abnormal dipstick test results, or a positive 
ratio of plasma aldosterone to plasma renin. Once lifestyle and 
adherence to therapy have been managed satisfactorily, the addition 
of a fourth-line drug should be considered. Resistant hypertension 
should, where possible, be managed by specialist physicians. Fourth-
line therapy drugs are listed below and users should be conversant 
with their pharmacology:
•	 direct vasodilators: hydralazine and minoxidil
•	 centrally acting drugs: methyldopa and moxonidine
Summary: management of acute stroke59
•	 Do not lower the BP or use antihypertensive medication unless 
the SBP >220 mmHg or DBP >120 mmHg – a rapid fall in BP 
may aggravate cerebral ischaemia and worsen the stroke
•	 If the BP is above these levels, then treatment should aim to 
lower the BP by no more than 15 - 20% in the first 24 hours
•	 Oral treatment may be given, but parenteral treatment may be 
warranted if the patient is unable to swallow
•	 The preferred parenteral drugs are those that are easily titrated 
and have a minimal effect on cerebral blood vessels (e.g. 
labetalol). Sodium nitroprusside should be administered in an 
ICU because of its rapid onset of action.
Summary
•	 Severe hypertension requires careful clinical evaluation to 
differentiate hypertensive emergency from hypertensive 
urgency and asymptomatic severe hypertension 
•	 This allows appropriate treatment decisions regarding level of 
care (hospitalisation and observations) and indicates the route 
of drug administration and rapidity of BP reduction
•	 Hypertensive emergency requires intensive clinical care
•	 Hypertensive urgency needs careful outpatient or short-stay 
management (preferable) and early follow-up
•	 Severe asymptomatic hypertension usually requires observation 
for 1 - 3 hours and early follow-up
•	 All require long-term follow-up and control of CV risk factors.
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•	 α-blockers: doxazosin
•	 β-blockers: many cardio-selective agents are available
•	 aldosterone antagonist: spironolactone61 and eplerenone.
9. Special considerations for 
hypertension in certain populations
9.1 Hypertension in blacks and Asians
Black persons are prone to complications such as stroke, heart failure 
and renal failure, while CHD – although emerging in frequency 
– is less common than in whites and Asians.62 Asians have a 
higher prevalence of diabetes mellitus and the metabolic syndrome 
compared with other racial groups.63 
Compared with white patients, black patients respond poorly 
to antihypertensive monotherapy with ACE-Is and β-blockers, but 
do respond well to these agents in combination therapy with 
diuretics. Overall, CCBs show the most consistent response in black 
hypertensive patients compared with other classes of drugs used as 
monotherapy.64,65
9.2 Hypertension in children and adolescents66,67 
Hypertension in children is an important issue beyond the scope 
of this guideline. Measurement of BP should be a routine part 
of paediatric examination, and the use of appropriate cuff size is 
essential. Hypertension in children is defined by a SBP and DBP 
greater than the 95th percentile  according to age, sex and height 
(Table XIII). Hypertension is seldom primary in childhood; a detailed 
investigation should be made for an underlying secondary cause. 
Referral to a specialist for evaluation and treatment is essential. 
In adolescents, hypertension is increasingly linked to obesity. 
Globally, poor diet and a lack of exercise in children is causing an 
epidemic of obesity, with an early onset of hypertension and Type 2 
diabetes. Early recognition of this hypertension will be an important 
motivation for children and their parents to institute important 
lifestyle changes.
9.3 Hypertension in pregnancy
Hypertensive disease in pregnancy is the leading cause of direct 
maternal deaths in South Africa. Pre-eclampsia is a multi-organ 
disease unique to pregnancy, clinically evident by the presence 
of hypertension and proteinuria. In severe form, pre-eclampsia is 
the most common cause of maternal and perinatal morbidity and 
mortality. 
9.3.1 Treatment 
Antihypertensive treatment should be instituted when SBP ≥160 
mmHg or DBP ≥110 mmHg. In the presence of other markers of 
potentially severe disease (e.g. thrombocytopenia, oliguria and/
or abnormal liver function), treatment should be initiated at lower 
degrees of hypertension. Diuretics and atenolol should generally be 
avoided, and ACE-Is and ARBs are contraindicated entirely. Suitable 
antihypertensive drugs to be used in pregnancy are:
Table XI. Intravenous and oral drugs for hypertensive emergency*
Drug Dose Indications and precautions Effect on BP
Intravenous
Nitroglycerine 
(glyceryl trinitrate)
5 - 10 µg/min Especially useful for myocardial 
ischaemia
BP lowering occurs in
2 - 5 min
Dihydralazine 10 mg every 10 - 15 min until 
either BP is controlled or a 
maximum of 50 mg given
Avoid in patients with myocardial 
ischaemia
BP lowering occurs in 10 min
Sodium nitroprusside 0.25 - 10 µg/kg/min diluted in 
5% dextrose and adjust dose as 
necessary
Admission to ICU
An intra-arterial BP line is 
desirable
BP control is immediate
Labetalol 2 mg/min to a total dose of 1 - 2 
mg/kg
Use where emergency caused by 
phaeochromocytoma caution in 
acute pulmonary oedema
Furosemide 40 - 80 mg Acts only for 6 hours
Potentiates all of the above drugs
Oral (use only if IV drugs are not available)
Nifedipine 
(long-acting only)
Long-acting CCBs must be used 
to prevent rapid and dangerous 
BP reduction
Check dosage according to CCB 
brand used
Preferred in black persons
Captopril 6.25 mg as a test dose Other rapidly acting ACE-I may be 
used starting with a low test dose
BP lowering in 15 - 30 min
Increase to 25 mg if BP lowering 
is not obtained in 15 - 30 min
DO NOT USE if bilateral renal 
artery stenosis is suspected
DO NOT USE if pregnancy is 
suspected
* For treatment of hypertensive emergency in pregnancy see section 9.3.
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•	 methyldopa (500 mg 6-hourly)
•	 nifedipine XL (30 - 60 mg daily)
•	 apresoline (25 - 50 mg 8-hourly)
•	 labetalol (100 - 200 mg twice per day, titrated to 600 mg if 
needed).
9.3.2 Hypertensive emergencies (impending eclampsia, eclampsia) 
Very high BP should be lowered with an infusion of labetalol: 5 
mg/ml at a rate of 4 ml/h via a syringe pump. The infusion rate 
should be doubled every 30 minutes to a maximum of 32 ml until 
the DBP has fallen and stabilised at an acceptable level (95 - 100 
mmHg).
Table XII. Causes of resistant hypertension in South Africa* 
Non-adherence to therapy Instructions not understood
Side-effects
Cost of medication and/ or cost of attending at healthcare centre
Lack of consistent and continuous primary care
Inconvenient and chaotic dosing schedules
Organic brain syndrome (e.g. memory deficit)
Volume overload Excess salt intake
Inadequate diuretic therapy
Progressive renal damage (nephrosclerosis)
Fluid retention from reduction of BP
Associated conditions Smoking
Increasing obesity
Sleep apnoea
Insulin resistance/hyperinsulinaemia
Ethanol intake of more than 30 g (3 standard drinks) daily
Anxiety-induced hyperventilation or panic attacks
Chronic pain
Intense vasoconstriction (Raynaud’s phenomenon), arteritis
Identifiable causes of hypertension Chronic renal disease
Renovascular disease
Primary aldosteronism
Coarctation
Cushing’s syndrome
Phaeochromocytoma
Pseudoresistance ‘White-coat hypertension’ or office elevations
Pseudo-hypertension in older patients
Use of regular cuff on very obese arm
Drug-related causes Doses too low
Wrong type of diuretic
Inappropriate combinations
Rapid inactivation (e.g. hydralazine)
Drug actions and interactions NSAIDs
Sympathomimetics: nasal decongestants; appetite suppressants
Cocaine and other recreational drugs: caffeine; oral contraceptives
Adrenal steroids
Liquorice (as may be found in chewing tobacco)
Cyclosporine, tacrolimus; erythropoietin
Antidepressants (monoamine oxidase inhibitors, tricyclics)
* Adapted from JNC VI.5
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Labetalol can also be used as an intermittent bolus infusion – 50 
mg (10 ml of labetalol 5 mg/ml) administered over at a period of at 
least 1 minute. This treatment should take effect within 5 minutes 
and should be repeated until the DBP is between 95 and 100 mmHg 
– to a maximum dose of 200 mg and provided that the pulse rate 
remains >60 bpm. Nifedipine is an alternative drug administered via 
a 10 mg oral tablet (not a slow-release tablet); it should not be given 
sublingually, chewed, bitten or used buccally.
9.4 Hypertension in persons living with HIV/AIDS
Prolonged highly active antiretroviral therapy (HAART) is 
associated with a higher prevalence of systolic hypertension.68 
Individuals receiving HAART may be at increased risk of developing 
hypertension-related conditions, underscoring the importance of 
monitoring their BP. When antiretroviral drugs are used, the doses of 
CCBs are invariably influenced, especially at the start, termination or 
change of therapy. Frequent BP and dose checks are advised. Two of 
the 3 major classes of antiretroviral drugs – protease inhibitors (PIs) 
and non-nucleoside reverse transcriptase inhibitors (NNRTIs) – are 
involved in many drug interactions by inhibition or induction of the 
key hepatic enzyme system, cytochrome P450. CCBs are the major 
class of antihypertensives affected by such drug interactions.68-70
The first-line antiretroviral regimen is currently based on NNRTIs 
(efavirenz or nevirapine) which are enzyme inducers, thereby 
promoting the metabolism of all currently available CCBs – via 
a poorly understood mechanism – and potentially reducing their 
antihypertensive effect. If the first-line regimen fails, therapy is 
changed to a PI regimen, which decreases the rate of CCB metabolism 
to increase CCB blood levels with the risk of hypotension. Particular 
care must be taken in patients receiving first-line antiretroviral 
therapy where the BP is controlled with CCBs. If the antiretroviral 
therapy is switched to include a PI, a dramatic fall in BP may result; 
it is therefore better to avoid CCBs with concurrent antiretroviral 
therapy.70 The metabolism of numerous β-blockers may be inhibited 
by PIs – a theoretical interaction of uncertain significance. It would 
be prudent to initiate a low-dose β-blocker treatment in patients 
receiving PIs.
9.5 Control of hypertension in diabetes
Diabetes is prevalent in South African Indians (15.8%)63 and whites 
(3.5%),71 and is becoming more common in blacks (4.8 - 6%).72 The 
illness has become the most common cause of end-stage renal disease 
(ESRD) because it is increasing in prevalence (particularly Type 2). 
Moreover, diabetic patients live longer at present, and are receiving 
treatment in ESRD programmes from which they were previously 
excluded.73 The onset and course of the disease can be ameliorated if 
measures are instituted early. 
ESRD is the most common complication of Type 1 diabetes. A 
higher proportion of individuals with Type 2 diabetes are found 
to have microalbuminuria and overt nephropathy shortly after 
diagnosis because the disease had been present for many years prior. 
A correlation exists between the degree of albuminuria and CVD. 
The guideline was abbreviated and therefore does not meet the 
detailed information required for the prevention and treatment of 
diabetes with hypertension in the SA population.73
The earliest clinical evidence of nephropathy – i.e. incipient 
nephropathy – is microalbuminuria (3 - 30 mg/mmol on spot 
urine). Microalbuminuria rarely occurs with a short duration of 
Type 1 diabetes; therefore, screening is necessary after 5 years of 
disease course. Because of the difficulty in precise dating of the 
onset of Type 2 diabetes, screening should begin at diagnosis.73 The 
Diabetes Control and Complications Trial74 and the United Kingdom 
Prospective Study75 have both shown that intensive therapy of blood 
sugar can significantly reduce the development of microalbuminuria 
and overt nephropathy in diabetic patients.
Hypertension in diabetes shows: (i) more ISH; (ii) more non-
dippers; (iii) abnormal BP regulation (variable with exercise and 
posture); (iv) a widened pulse pressure; (v) a correlation between SBP, 
heart failure and CV disease in Type 2 diabetes; and (vi) impaired 
sodium handling by the kidneys. In patients with Type 2 diabetes, 
hypertension is present in about one-third of patients at the time of 
diagnosis. Hypertension in diabetes is aggressive and progressive; it 
progresses rapidly to renal failure unless aggressively treated. The 
ACE-I, captopril, relieves albuminuria and prevents the progression 
of renal disease in Type 1 diabetes.76 Studies have shown that ACE-Is 
reduce the progression of microalbuminuria in Type 2 diabetes,77 and 
prevent the onset of microalbuminuria.
The combination of a third-generation dihydropyridine CCB 
(manidipine) and an ACE-I (delapril) failed to slow GFR but safely 
ameliorated CVD, retinopathy and neuropathy in the DEMAND 
study, involving 380 hypertensive Type 2 diabetic patients with 
albuminuria <200 mg/min. Notably, treatment was well tolerated, 
and the trial was double-blind, placebo-controlled and randomised 
to a 3-year follow-up.78 Because of the high proportion of patients 
Table XIII. 95th percentile of BP in boys and girls aged 3 - 16 years, according to age, sex and height*
Age Height percentile (boys) Height percentile (girls) 
(years) 5th 25th 75th 95th 5th 25th 75th 95th
SBP (mmHg)
3 104 107 111 113 104 105 108 110
6 109 112 115 117 108 110 112 114
10 114 117 121 123 116 117 120 122
13 121 124 128 130 121 123 126 128
16 129 132 136 138 125 127 130 132
DBP (mmHg)
3 63 64 66 67 65 65 67 68
6 72 73 75 76 71 72 73 75
10 77 79 80 82 77 77 79 80
13 79 81 83 84 80 81 82 84
16 83 84 86 87 83 83 85 86
* The height percentiles were determined with standard growth curves. Data are adapted from those of the Task Force on High Blood Pressure in Children and Adolescents.67
78 January 2012, Vol. 102, No. 1  SAMJ
who progress from microalbuminuria to overt nephropathy in 
ESRD, the use of ACE-Is or ARBs is recommended for all patients 
with microalbuminuria or advanced stages of nephropathy.76, 77 The 
decision to use either an ACE-I or ARB in Type 2 diabetes should be 
left to the physician, with consideration of the affordability of therapy. 
The metabolic syndrome has been described in the black population 
in the Free State72 and the Indian population in Durban.63,79 Owing to the 
diabetogenic effects of a thiazide-like diuretic used concomitantly with 
a β-blocker,80 this treatment is probably inadvisable in such patients.63,79 
If it is necessary to use combination therapy to obtain the desired target 
BP	 (≤130/80	mmHg),	 an	ACE-I	 or	ARB	 should	 be	 combined	with	 a	
thiazide-like diuretic (in the absence of gout or hyperuricaemia) or CCB, 
as these combinations have synergistic effects.
Patients with diabetic nephropathy are at very high CV risk, and 
there should be effective control of common CV risk. Patients should 
stop smoking, receive salicylates 80 - 150 mg daily (provided that 
the BP is controlled), and statins (and/or fibrates if indicated). In 
all stages of nephropathy, a BP <130/80 mmHg and blood HbA1c 
level<7% should be targeted. Albumin excretion should be monitored 
annually (albumin/creatinine ratio on spot urine). Treatment with an 
ACE-I or ARB is the preferred initial choice, combined with other 
antihypertensive drugs.
In more advanced nephropathy (CKD stages 4 and 5) the following 
should be observed: (i) glycaemic control must be modified due to 
risks of hypoglycaemia and metabolic acidosis related to metformin; 
(ii) BP <130/80 mmHg should be targeted, and furosemide twice 
daily should be considered; (iii) ACE-Is or ARBs should be continued 
(but with extreme caution in CKD stage 5), with awareness of the 
risks of hyperkalaemia and acute decline in renal function; and 
(iv) malnutrition should be avoided, but protein and phosphate 
restriction can be considered. Dialysis and renal transplantation 
should be considered in suitable cases with end-stage disease.
10. Primordial prevention
The main objective is to avoid or decrease the social, economic 
and cultural determinants that contribute to the development of 
hypertension. Primordial prevention relies on health policies that 
create a congenial environment in which healthy behaviour and 
population-wide education programmes are encouraged. In turn, 
policies rely on many factors, including political commitment, 
advocacy by health professionals, and involvement of community 
leaders and the mass media. Strategies are intended to prevent 
the acquisition or enhancement of CVD risk factors, particularly 
lifestyle and diet changes in black patients brought about by rapid 
urbanisation.80 The approach should be non-pharmacological, 
population-based and lifestyle-linked. Development of cost-effective 
methods for diagnosis and cost-saving measures for all risk factors of 
CVD is needed.
11. Prevention of hypertension
Prevention of hypertension is reliant upon the adoption of strict 
lifestyle measures. The prevalence of hypertension and CVD is 
increasing rapidly in Sub-Saharan Africa.80 In a study of hypertension 
in Tanzania, under 20% of hypertensive subjects were aware of their 
diagnosis, approximately 10% reported receiving treatment, and less 
than 1% had controlled BP (<140/90 mmHg).81 Similarly, the treatment 
status for South African black males showed that 20% were aware of 
their hypertension, 14% were receiving treatment and only 7% had 
controlled BP. In females, 47% were aware of their hypertension, 29% 
were receiving treatment and only 15% had controlled BP.11
12. Patient education
Hypertensive patients have the right to be informed about the 
status and progress of their condition. The main objective of patient 
education is to empower individuals to participate actively and 
ensure the quality of the management of their hypertension. Effective, 
honest and open two-way communication between the care provider 
and the patient is critical to the management of chronic life-long 
conditions. Acquisition of communication and counselling skills by 
health professionals is essential – preferably in the language of the 
target population. A checklist to guide the content of hypertensive 
patient education is provided in Annexure B. Poor adherence 
to therapy is the central cause of uncontrolled BP; obstacles to 
adherence are shown in Table XIV.
13. Ongoing management of the 
patient with hypertension
•	 Dose titration or stepwise increase should be carried out after 2 
months if the BP remains uncontrolled and adherence is a factor
•	 Once a stable target BP has been achieved, follow-up BP 
measurement should be performed every 3 - 6 months
•	 Drug dose should be reduced if the patient presents with symptoms 
of postural hypotension (i.e. dizziness or SBP fall >20 mmHg on 
standing)
•	 Refer the patient from primary care to higher level care in the 
following:
•	 Young patients (18 - 30 years)
•	 Pregnancy
•	 Resistant hypertension (uncontrolled BP despite treatment with 
3 drugs)
Table XIV. Obstacles to adherence
Treatment characteristics Patient and illness characteristics
Long duration of therapy Asymptomatic nature of the condition leave people feeling that they are not ill
Complicated regimens Chronic conditions require constant attention
Expensive medications There are no immediate consequences of stopping therapy, e.g. one does not feel sick
Side-effects of medications Social isolation
Lack of specific appointment times Disrupted home situation
Long waiting period at clinic or office Psychiatric illnesses
Lack of consistent and continuous primary care
Instructions not understood
Organic brain syndrome (e.g. memory deficit)
Medicines not available
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•	 Any patient with severe TOD and/or severe ACC (most patients 
with high added risk or very high added risk)
•	 Hypertensive urgency or emergency.
•	 Most patients with low or moderate added risk can be managed 
at primary care level (general practitioner or clinic nurse) and 
assessed every 6 months. Patients with high or very high added 
risk with numerous risk factors should be managed by physicians 
or medical subspecialists (cardiologists, nephrologists and 
endocrinologists) and healthcare professionals with a special 
interest in hypertension; these patients may need frequent visits 
until the BP is controlled.
14. Strategic implications for 
implementing this guideline
This section was developed by the Department of Health (DoH) 
and has been included as Annexure C. The SAHS endorses the 
strategy, which is mainly for policy-makers or those who administer 
healthcare facilities. Implementation of the guideline is an active 
process requiring more than dissemination and education; it 
requires the full collaboration and co-operation of policy makers, 
administrators and funders. The DoH and SAHS are committed to 
the full implementation of this guideline.
15. Disclaimer
This national clinical guideline is for educational and reference 
purposes only. It is not intended to be a substitute for the advice of 
the appropriate healthcare professional or for independent research 
and judgment. The SAHS accepts no responsibility or liability arising 
from any information contained within the guideline, or any error 
of omission from the protocol or from the use of any information 
contained within it.
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Annexure A: Abbreviations
ABP ambulatory blood pressure
ABPM ambulatory blood pressure monitoring
ACC associated clinical conditions
ACE-I angiotensin-converting enzyme inhibitor
ARB angiotensin II receptor blocker
AV atrioventricular
BMI body mass index
BP blood pressure
CCB calcium channel blocker
CHD coronary heart disease
CKD  chronic kidney disease
CV cardiovascular
CVD cardiovascular disease
DBP diastolic blood pressure
DoH Department of Health
ECG electrocardiogram
ESRD end-stage renal disease
FDC fixed drug combination
GFR glomerular filtration rate
HDL high-density lipoprotein
HDL-C high-density lipoprotein cholesterol
HF heart failure
ICU intensive care unit
ISH isolated systolic hypertension
LDL low-density lipoprotein
LDL-C low-density lipoprotein cholesterol
LV left ventricle
LVH left ventricular hypertrophy
MI myocardial infarction
NNRTI non-nucleoside reverse transcriptase inhibitors
NSAIDs non-steroidal anti-inflammatory drugs
PI protease inhibitor
SAHS Southern African Hypertension Society
SBP systolic blood pressure
SBPM self blood pressure monitoring 
TC total cholesterol
TIA transient ischaemic attack
TOD target organ damage
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Annexure B: Checklist for therapeutic patient education 
The major objective is to empower all patients to participate actively in the management of their non-communicable chronic diseases/
conditions.

Provide information to patients so that they can understand hypertension and its consequences if not treated adequately. 
Involve the patient and family or care-giver in the management.

Inform patients of the distinction between having a risk factor and having a disease, and the benefits of controlling risk factors. 
Reinforce the importance of lifestyle modification at each visit. 
Inform patients of their BP reading at every visit and whether BP is controlled or what the target should be. 
Emphasise the importance of adherence to the management protocol. 
Patients must know the name, strength and dose of the drug(s) prescribed, dose frequency, and the necessity of regular 
ongoing use.

Inform patients on how to deal with side-effects. 
Patients must be made aware of drug interactions and food/drug interactions. 
Tell patients to take the morning dose on the day of each visit to the health service. 
Ask patients to return drug containers, even if they are empty, at each visit. 
Support groups for the patients are essential and need to be established at all facilities. The focus should be on self-care and 
self-monitoring, emotional needs, cultural differences, discrimination, change management and behavioural change.

Counsel patients with hypertension who may have an excessive fear of strokes or other consequences of hypertension. 
Educate patients to inform all healthcare providers consulted, that they do have hypertension and which drugs they are taking. 
Encourage patients to request a BP measurement at each visit. 
Annexure C: Strategic implications for the implementation of this guideline 
This section, developed by the SAHS, is mainly for those who administer healthcare facilities or make policy. The implementation of the 
guideline is an active process involving more that dissemination and education. It requires the full collaboration and co-operation of 
policy makers, administrators and funders. SAHS is committed to the full implementation of this guideline. The key elements of focus to 
improve the management of hypertension and any other non-communicable chronic diseases/conditions are:
Communication Partnerships – working together to deliver best possible care
Continuity Performance – deliver quality care
Coordination Professions – the right people delivering service
Comprehensiveness Patient access – deliver fast and convenient care
Community linkages Patient empowerment – rights and needs are met
Caring ethos Prevention – promote healthy living
Care of high quality
Competence
•	 If the above key elements are considered, it will: 
•				Enable	the	creation	of	long-term	innovative	care	models	suitable	for	developing	communities,	and	prevent	non-communicable	chronic	
diseases and associated risk factors from developing
•				Control	the	progression	of	the	non-communicable	chronic	diseases	or	their	risk	factors,	increase	survival	and	enhance	quality	of	life
•				Allow	health	professionals,	patients	and	families	to	share	complementary	knowledge	and	skills,	thereby	allow	patients	to	become	active	
partners in the management of their non-communicable diseases
•				Allow	for	a	lifestyle,	drug	and	self-management	strategy	with	community	and	family	support
•				Encourage	a	broad	spectrum	of	care	organisations,	professionals	and	informal	caregivers	to	participate.
•	 Patient-centred care and service is desired where there is one-to-one communication and group education. Inform patients on how, 
where and when to access help. A patient-oriented, tolerant, caring, concerned attitude is required from healthcare providers. Be 
sensitive to patients’ socio-economic conditions and cultural history. Empathic communication builds trust and is a potent motivator. 
Implement long-term care models where there is a dedicated care provider, dedicated clinic time, chronic disease register, etc.
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Annexure C: Strategic implications for the implementation of this guideline  – continued
•	 A paradigm shift is needed to adjust the health delivery system. To make a tangible difference in non-communicable disease 
morbidity and mortality, a paradigm shift is required. In order to enhance this paradigm shift, movement from a single risk-factor 
approach to a comprehensive risk-management approach is needed, and chronic/long-term care models need to be implemented. 
Effective chronic/long-term care requires a different kind of healthcare delivery system in which there is coordinated comprehensive 
care: i.e. a move from a ‘find it and fix it’ model to one of coordinated and comprehensive continuum of care over extended regular 
contact. The implementation of dedicated services is a clinic organisational issue and it should be implemented at primary level for 
chronic diseases. Strengthen and decentralise resources and the provision of care for patients with non-communicable chronic diseases 
and disabilities at primary level. The chronic long-term care model differs from acute care models and the delivery of service should 
reflect this.
•	 Institute dedicated hypertension service (i.e. team and time) by using a team of health professionals specifically assigned to deal with 
hypertensive patients. Wherever possible, patients should see the same healthcare provider at each visit. The team members should be 
appropriately trained and carefully selected, and not rotated. Rotation makes training one of the major cost drivers in the delivery of 
long-term care. An overall coordinator for chronic care/long-term care should be selected and should be responsible for the treatment 
outcomes in the facility. All patients with hypertension require a dedicated time, day, etc. Alternative measures should be implemented 
if dedicated hypertension health professionals are not available. 
•	 Patients should never be treated at the same time as patients with acute, curable disease, unless the latter is the reason for visiting the 
clinic. This will require an effective triage system. The hallmarks of a dedicated hypertension service/care are:
•    Effective: with the right level of care provided at the right time, by the right persons
•    Efficient: with appropriate integrated care packages across the levels of care – this will require an effective, well-defined referral system, 
known to patients and healthcare providers and even an appointment system
•    Informative: with patient access to understandable information that allows them to make rational decisions about care options, treatment, 
laying of complaints, etc.
•    Equitable: all patients should benefit from service/care that is consistent, continuous, available and accessible
•    Promotive and preventive: such aspects must be included in the integrated hypertension care package: e.g. therapeutic education, life 
skills training, etc.
•	 Adequate equipment must be available to perform the tasks and observations as listed in this guideline.
•	 Drug therapy: relevant and appropriate drugs should be available at all times and not be changed, except by the prescriber. Patients should 
receive the total amount of drugs as prescribed. Procurement and distribution systems should be more effective.
•	 National record-keeping in the form of chronic disease registers should be implemented in all care facilities to monitor patient control and 
compliance. 
•	 The patient/healthcare provider ratio should be reasonable.
•	 Patient record/file management should be sequential and systematic with each entry dated and signed as appropriate. All information 
should be documented on the record and no loose papers or stickers should be allowed. 
•	 Self-monitoring equipment should be made available to those patients as recommended in the SBPM (see section 3.3). Each support group 
must have validated SBPM devices for group use.
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